Germany: drug-related information and data
Germany
Our partner in Germany
Parzivalstraße 25
D-80804 München
Tel. +49 8936080440
Fax +49 8936080449
Head of focal point: Mr Tim Pfeiffer-Gerschel
After establishment of the European Monitoring Centre for Drugs and Drug Addiction in 1993, the German Ministry for Health nominated the Federal Centre for Health Education (Bundeszentrale für gesundheitliche Aufklärung, BZgA, Cologne), the German Centre for Addiction Issues (Deutsche Hauptstelle für Suchtfragen e.V., DHS, Hamm) and the IFT Institute for Therapy Research (IFT Institut für Therapiefoschung, Munich) to act jointly as the German national focal point within the Reitox network of the EMCDDA. Together, the three institutions form the German Monitoring Centre for Drugs and Drug Addiction (DBDD) with the IFT as the responsible overall management institution of the NFP. Within the DBDD, the BZgA deals with prevention aspects, the DHS is mainly responsible for the working areas ‘addiction treatment’ and ‘harm reduction’ and the IFT is responsible for epidemiology, scientific coordination and overall management of the NFP. A formal agreement which was accepted by the Ministry for Health in 1999, forms the basis of the interinstitutional cooperation. The DBDD works closely together with the German representatives within the EMCDDA: Mechthild Duckmans, the German national drug commissioner, represents Germany within the EMCDDA’s Management Board, together with Mr Dirk Lesser, who represents the Federal Länder. Prof. Dr Gerhard Bühringer (IFT Munich, University of Dresden) is the German member and Vice-Chair of the EMCDDA Scientific Committee.E-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses.
Country situation summaries are written with the general reader in mind and provide short, mainly text-based analyses of national drug situations.
Key data sheets provide an at-a-glance statistical view of the drug situation by country and cover areas including prevalence, problem drug use, infectious diseases, deaths, and more.
Country barometers provide a graphical representation of drug use prevalence data for each country, showing its position relative to other countries by population and drug.
What are countries in Europe doing to prevent illicit drug use? 'Prevention profiles' attempts to answer this question using interactive maps and data charts based on expert appraisals.
Legal profiles describe national drug-related legislation in a standardised, comparable format. Topics covered include possession, trafficking, classification, prosecution, prevention, treatment, among others.
This resource provides access to the current national strategies and action plans for each country as well as a brief description of recent and ongoing work in the area.
Each treatment profile provides information on the national context, treatment registries and monitoring systems, treatment demand, availability of treatment services as well as references and resources.
Each overview describes: the national context; references and resources; key responses for preventing and reducing drug-related infectious diseases and; drug-related deaths and drug-related harms in recreational settings.
These data sheets on drug-related public expenditure cover 30 countries and examine how much countries spend on drug-related activities, whether there are specific budgets allocated to drug policy documents, and how drug-related expenditure has evolved over time.
National reports draw an overall picture of the drug phenomenon at national level. The data is an important resource, among others for the compilation of the EMCDDA's Annual report.
National drug related research provides information by country in the following areas: main funding frameworks, research institutions, scientific journals, websites, main studies conducted and articles published.
